YI vs. ALUR, PASG, ORMP, ADAG, BYSI, BLUA, CLSD, ETON, ACRS, and CRIS
Should you be buying 111 stock or one of its competitors? The main competitors of 111 include Allurion Technologies (ALUR), Passage Bio (PASG), Oramed Pharmaceuticals (ORMP), Adagene (ADAG), BeyondSpring (BYSI), BlueRiver Acquisition (BLUA), Clearside Biomedical (CLSD), Eton Pharmaceuticals (ETON), Aclaris Therapeutics (ACRS), and Curis (CRIS). These companies are all part of the "medical" sector.
111 (NASDAQ:YI) and Allurion Technologies (NYSE:ALUR) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, dividends, valuation, profitability, community ranking, media sentiment and analyst recommendations.
21.3% of 111 shares are owned by institutional investors. Comparatively, 21.4% of Allurion Technologies shares are owned by institutional investors. 43.9% of 111 shares are owned by company insiders. Comparatively, 20.0% of Allurion Technologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
In the previous week, 111 had 7 more articles in the media than Allurion Technologies. MarketBeat recorded 9 mentions for 111 and 2 mentions for Allurion Technologies. Allurion Technologies' average media sentiment score of 0.33 beat 111's score of 0.30 indicating that Allurion Technologies is being referred to more favorably in the news media.
111 received 188 more outperform votes than Allurion Technologies when rated by MarketBeat users. However, 100.00% of users gave Allurion Technologies an outperform vote while only 61.69% of users gave 111 an outperform vote.
Allurion Technologies has a net margin of 0.00% compared to 111's net margin of -2.62%.
111 has higher revenue and earnings than Allurion Technologies.
Allurion Technologies has a consensus target price of $5.00, suggesting a potential upside of 155.10%. Given Allurion Technologies' higher possible upside, analysts clearly believe Allurion Technologies is more favorable than 111.
111 has a beta of 0.36, indicating that its stock price is 64% less volatile than the S&P 500. Comparatively, Allurion Technologies has a beta of -0.13, indicating that its stock price is 113% less volatile than the S&P 500.
Summary
111 and Allurion Technologies tied by winning 7 of the 14 factors compared between the two stocks.
Get 111 News Delivered to You Automatically
Sign up to receive the latest news and ratings for YI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding YI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
